Our Pricing

Understanding Asda Mounjaro Availability and UK Pricing Options

Searching for Asda Mounjaro pricing and availability? While Asda pharmacies may stock Mounjaro subject to local availability and NHS prescription requirements, many UK patients now access this treatment through registered online pharmacies like Cured Pharmacy, where transparent pricing starts from £135.00 with a free clinical consultation completed in under three minutes.

Asda Mounjaro Availability: What You Need to Know

Asda pharmacies across the UK may dispense Mounjaro (tirzepatide) when you present a valid NHS or private prescription, though stock availability varies by location and is subject to national supply considerations. As a prescription-only medication licensed by the MHRA, Mounjaro cannot be purchased over the counter at any UK pharmacy, including Asda.

Many patients find that online registered pharmacies offer greater transparency around pricing and availability. At Cured Pharmacy (GPhC 9012511), you'll see the exact cost before your consultation, and our UK prescribers can assess your suitability and issue a prescription if clinically appropriate—all without visiting a physical pharmacy.

How Much Does Asda Mounjaro Cost Compared to Private Online Pharmacies?

Asda pharmacies dispense Mounjaro at the price determined by your prescriber's prescription, whether NHS or private. For private prescriptions, costs typically reflect the wholesale price plus pharmacy dispensing fees, which can vary significantly between locations and pharmacy groups across the UK.

At Cured Pharmacy, Mounjaro pricing is transparent and competitive: treatment starts from £135.00, with the final cost depending on your prescribed dose following clinical assessment by our UK-registered prescribers [1]. This includes the medication, prescription service, and discreet home delivery—no hidden fees or surprise charges at checkout.

Our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures every prescription meets MHRA standards and that patients receive genuine UK-licensed medication. Unlike traditional pharmacy models where pricing may only become clear at the counter, we believe patients deserve to know costs upfront before beginning their consultation.

Why Pricing Varies Between Pharmacies

UK pharmacy pricing for private prescriptions isn't regulated in the same way as NHS prescriptions, which means each pharmacy sets its own fees for dispensing and delivery. Factors affecting cost include wholesale purchasing agreements, dispensing fees, delivery charges, and consultation costs where applicable. Online pharmacies often achieve lower operational costs than high-street branches, allowing more competitive pricing whilst maintaining the same regulatory standards.

Understanding Mounjaro: How Tirzepatide Works for Weight Loss

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed in the UK for chronic weight management. Unlike single-pathway treatments, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, producing enhanced effects on appetite regulation, glucose metabolism, and body weight reduction [1].

In the landmark SURMOUNT-1 trial, participants receiving the highest maintenance dose of tirzepatide achieved an average body weight reduction of 22.5% over 72 weeks—significantly greater than results seen with semaglutide-based alternatives in comparable trials [1][2]. These results positioned tirzepatide as one of the most effective pharmacological treatments for obesity currently available in the UK.

The medication works by slowing gastric emptying, reducing appetite, and improving insulin sensitivity. Patients typically report feeling fuller for longer periods and experiencing reduced food cravings, which supports sustainable dietary changes alongside the medication's metabolic effects [1].

Clinical Trial Evidence

The SURMOUNT clinical trial programme demonstrated tirzepatide's efficacy across diverse patient populations. In SURMOUNT-2, which specifically enrolled participants with type 2 diabetes, average weight loss reached 15.7% with the 15mg dose over 72 weeks [3]. These trials informed MHRA licensing decisions and established the evidence base UK prescribers use when assessing patient suitability.

NHS vs Private Mounjaro Prescriptions: Key Differences

Mounjaro is licensed in the UK for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity. However, NHS availability remains extremely limited due to NICE guidance restrictions and local formulary decisions, meaning most patients cannot currently access Mounjaro through NHS prescription [4].

Private prescriptions offer an alternative pathway for eligible patients. Through registered online pharmacies like Cured Pharmacy, UK prescribers can assess your medical history, current medications, and weight management goals during a confidential consultation. If clinically appropriate, they'll issue a private prescription that our pharmacy team dispenses and delivers discreetly to your home.

The consultation process at Cured Pharmacy takes under three minutes to complete online. Our prescribers evaluate the same clinical criteria used in NHS settings—including your BMI, previous weight loss attempts, contraindications, and relevant medical history—to determine whether Mounjaro represents a safe and suitable treatment option for you.

Asda Mounjaro vs Alternative Weight Loss Treatments

Whether you're considering Asda Mounjaro or exploring other options, understanding the differences between available treatments helps inform your decision. Mounjaro (tirzepatide) offers dual-receptor activation, whilst Wegovy and Saxenda contain semaglutide and liraglutide respectively—both single-pathway GLP-1 receptor agonists with their own clinical evidence bases [2][5].

Wegovy demonstrated average weight loss of 15.3% over 68 weeks in the STEP-1 trial, making it another highly effective option for many patients [2]. Saxenda, administered as a daily injection rather than weekly, showed average weight loss of 8% over 56 weeks in clinical trials [5]. Your prescriber will consider factors including your medical history, injection frequency preference, and previous treatment responses when recommending the most suitable option.

Non-injectable alternatives like Orlistat work through a different mechanism—blocking fat absorption in the digestive system rather than affecting appetite hormones. Orlistat may suit patients who prefer oral medication or have contraindications to GLP-1 treatments, though clinical trial data shows more modest weight loss outcomes compared to tirzepatide or semaglutide [6].

Choosing Between Treatments

Your UK prescriber will assess multiple factors when recommending a treatment: your BMI and weight loss goals, any existing medical conditions (particularly cardiovascular disease or type 2 diabetes), previous weight loss attempts, medication preferences regarding injection frequency, and potential contraindications. At Cured Pharmacy, our clinical team takes time to understand your individual circumstances before making evidence-based recommendations.

Starting Mounjaro Treatment: What to Expect

Mounjaro treatment follows a structured dose escalation schedule designed to minimise gastrointestinal side effects whilst optimising weight loss outcomes. All patients begin with the 2.5mg starter dose, administered once weekly via subcutaneous injection using the pre-filled KwikPen device [1].

After four weeks, your prescriber will typically increase your dose to 5mg weekly, with further increases every four weeks until reaching your maintenance dose—usually 10mg or 15mg depending on your response and tolerability. This gradual escalation allows your body to adapt to the medication and significantly reduces the likelihood of nausea, vomiting, or other gastrointestinal symptoms that can occur with GLP-1 treatments [1].

Most patients at Cured Pharmacy report that injections become routine within the first few weeks. The KwikPen device features a hidden needle and simple push-button mechanism, making self-administration straightforward even for patients who feel anxious about injections. Our pharmacy team provides detailed administration guidance with every prescription, and you can contact us on (+44) 116 4646009 if you have questions during your treatment journey.

Managing Side Effects

The most common side effects of Mounjaro are gastrointestinal—including nausea, diarrhoea, reduced appetite, and occasional vomiting—particularly during dose escalation phases [1]. These symptoms typically improve within a few weeks as your body adjusts. Eating smaller meals, avoiding high-fat foods, and staying well-hydrated can help manage these effects. If side effects become troublesome, your prescriber may adjust your escalation schedule or recommend remaining on a lower dose for an additional month before increasing further.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–218. https://doi.org/10.1056/NEJMoa2206038
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Garvey, W. T., Frias, J. P., Jastreboff, A. M., et al. (2023). Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2): A Double-Blind, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial. The Lancet, 402(10402), 613–626. https://doi.org/10.1016/S0140-6736(23)01200-X
4. National Institute for Health and Care Excellence. (2023). Tirzepatide for Managing Overweight and Obesity [TA888]. NICE. https://www.nice.org.uk/guidance/ta888
5. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
6. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: A Randomized Study of Orlistat as an Adjunct to Lifestyle Changes for the Prevention of Type 2 Diabetes in Obese Patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on multiple factors including diet, exercise, and adherence to treatment. Clinical trial data represents average outcomes and does not guarantee individual results.